Literature DB >> 11914880

FDG PET in the management of lymphoma: a clinical perspective.

P J Hoskin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11914880     DOI： 10.1007/s00259-001-0755-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  15 in total

1.  Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease.

Authors:  E Wiedmann; B Baican; A Hertel; R P Baum; K U Chow; B Knupp; S Adams; G Hör; D Hoelzer; P S Mitrou
Journal:  Leuk Lymphoma       Date:  1999-08

2.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.

Authors:  S Partridge; A Timothy; M J O'Doherty; S F Hain; S Rankin; G Mikhaeel
Journal:  Ann Oncol       Date:  2000-10       Impact factor: 32.976

3.  2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.

Authors:  I Buchmann; M Reinhardt; K Elsner; D Bunjes; C Altehoefer; J Finke; E Moser; G Glatting; J Kotzerke; C A Guhlmann; H Schirrmeister; S N Reske
Journal:  Cancer       Date:  2001-03-01       Impact factor: 6.860

4.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

Authors:  F Moog; M Bangerter; C G Diederichs; A Guhlmann; J Kotzerke; E Merkle; O Kolokythas; F Herrmann; S N Reske
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

5.  Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.

Authors:  M Bangerter; J Kotzerke; M Griesshammer; K Elsner; S N Reske; L Bergmann
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

Review 6.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?

Authors:  L Kostakoglu; S J Goldsmith
Journal:  Eur J Nucl Med       Date:  2000-10

7.  18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.

Authors:  N G Mikhaeel; A R Timothy; M J O'Doherty; S Hain; M N Maisey
Journal:  Leuk Lymphoma       Date:  2000-11

8.  Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.

Authors:  M Bangerter; F Moog; I Buchmann; J Kotzerke; M Griesshammer; M Hafner; K Elsner; N Frickhofen; S N Reske; L Bergmann
Journal:  Ann Oncol       Date:  1998-10       Impact factor: 32.976

9.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.

Authors:  J S Newman; I R Francis; M S Kaminski; R L Wahl
Journal:  Radiology       Date:  1994-01       Impact factor: 11.105

10.  Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  G Jerusalem; V Warland; F Najjar; P Paulus; M F Fassotte; G Fillet; P Rigo
Journal:  Nucl Med Commun       Date:  1999-01       Impact factor: 1.690
View more
  3 in total

Review 1.  PET in lymphoma: what are the oncologist's needs?

Authors:  P J Hoskin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-04       Impact factor: 9.236

Review 2.  Role and cost effectiveness of PET/CT in management of patients with cancer.

Authors:  Muhammad Wasif Saif; Ifigenia Tzannou; Nektaria Makrilia; Kostas Syrigos
Journal:  Yale J Biol Med       Date:  2010-06

Review 3.  PET and restaging of malignant lymphoma including residual masses and relapse.

Authors:  S N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-14       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.